Literature DB >> 31858509

Limited diagnostic accuracy and clinical impact of single-operator peroral cholangioscopy for indeterminate biliary strictures.

Adriaan B de Vries1, Frans van der Heide1, Rinze W F Ter Steege2, Jan Jacob Koornstra1, Karel T Buddingh3, Annette S H Gouw4, Rinse K Weersma1.   

Abstract

BACKGROUND: Single-operator peroral cholangioscopy (sPOCS) is considered a valuable diagnostic modality for indeterminate biliary strictures. Nevertheless, studies show large variation in its characteristics and measures of diagnostic accuracy. Our aim was to estimate the diagnostic accuracy of sPOCS visual assessment and targeted biopsies for indeterminate biliary strictures. Additional aims were: estimation of the clinical impact of sPOCS and comparison of diagnostic accuracy with brush cytology.
METHODS: A retrospective single-center study of adult patients who underwent sPOCS for indeterminate biliary strictures was performed. Diagnostic accuracy was defined as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The clinical impact of sPOCS was assessed by review of medical records, and classified according to its influence on patient management.
RESULTS: 80 patients were included, with 40 % having primary sclerosing cholangitis (PSC). Prior ERCP was performed in 88 %, with removal of a biliary stent prior to sPOCS in 55 %. The sensitivity, specificity, PPV, and NPV for sPOCS visual impression and targeted biopsies were 64 %, 62 %, 41 %, and 84 %, and 15 %, 65 %, 75 %, and 69 %, respectively. The clinical impact of sPOCS was limited; outcome changed management in 17 % of patients. Sequential brush cytology sensitivity, specificity, PPV, and NPV were 47 %, 95 %, 80 %, and 83 %.
CONCLUSIONS: The diagnostic accuracy of sPOCS for indeterminate biliary strictures was found to be inferior to brush cytology, with a low impact on patient management. These findings are obtained from a select patient population with a high prevalence of PSC and plastic stents in situ prior to sPOCS. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Year:  2019        PMID: 31858509     DOI: 10.1055/a-1061-7067

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  7 in total

1.  Cholangioscopy and its Role in Primary Sclerosing Cholangitis.

Authors:  Brian M Fung; M Phillip Fejleh; Sooraj Tejaswi; James H Tabibian
Journal:  Eur Med J Hepatol       Date:  2020-06-04

Review 2.  Management of primary sclerosing cholangitis and its complications: an algorithmic approach.

Authors:  Michal Prokopič; Ulrich Beuers
Journal:  Hepatol Int       Date:  2020-12-30       Impact factor: 6.047

Review 3.  Role of Endoscopy in Primary Sclerosing Cholangitis.

Authors:  Purnima Bhat; Lars Aabakken
Journal:  Clin Endosc       Date:  2020-05-08

4.  Bile is a reliable and valuable source to study cfDNA in biliary tract cancers.

Authors:  Zhanghui Li; Yelei Liu; Junhui Fu; Joseph Mugaanyi; Junrong Yan; Caide Lu; Jing Huang
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

5.  Cholangioscopy in primary sclerosing cholangitis: a case series of dominant strictures and cholangiocarcinoma.

Authors:  Sooraj Tejaswi; Kristin A Olson; Thomas W Loehfelm
Journal:  VideoGIE       Date:  2021-03-18

6.  Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study.

Authors:  Xiang Wang; Xiao-Hui Fu; Zi-Liang Qian; Teng Zhao; An-Qi Duan; Xiang Ruan; Bin Zhu; Lei Yin; Yong-Jie Zhang; Wen-Long Yu
Journal:  Transl Oncol       Date:  2020-10-12       Impact factor: 4.243

7.  Peroral Cholangioscopy-Guided Targeted Biopsy versus Conventional Endoscopic Transpapillary Forceps Biopsy for Biliary Stricture with Suspected Bile Duct Cancer.

Authors:  Katsunori Sekine; Ichiro Yasuda; Shinpei Doi; Noriyuki Kuniyoshi; Takayuki Tsujikawa; Yuichi Takano; Masatoshi Mabuchi; Kosuke Takahashi; Masashi Kawamoto; Mikiko Takahashi; Tatsuya Aso; Tatsuhiko Miyazaki; Takuji Iwashita
Journal:  J Clin Med       Date:  2022-01-06       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.